China Pharma Holdings, Inc.

CPHIAMEXHealthcare● Active

$0.71

$-0.01(-0.82%)

Market Cap$2256873

P/E Ratio—

52W High$2.05

52W Low$0.38

Avg Volume277K

Open$0.72

Beta1.00

Overview

China Pharma Holdings, Inc. (CPHI) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CPHI · free cash flow · updated Jun 8, 2026

Core FCF metrics

CPHI · FCF · TTM · margin & CAGR

Free cash flow was $11,010 for FY2025 (fiscal year ending 2025-12-31), up 101.5% year-over-year The FCF margin was 0.3%.

FY2025 Free Cash Flow$11,010▲ +101.5% YoY

Trailing 12M (TTM)$134,492trailing 4 quarters sum

FCF Margin0.3%$11,010 ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

CPHI · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$148,261(0M)$11,010▲ +101.5%0.3%

FY2024−$466,362(0M)−$758,080▼ 6.6%-16.7%

FY2023−$699,686(0M)−$711,203▲ +12.4%-10.1%

FY2022−$409,545(0M)−$811,509▼ 18.0%-10.0%

FY2021−$249,838(0M)−$687,893▲ +24.4%-7.1%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

CPHI · P/FCF · FCF yield · FCF per share

China Pharma Holdings, Inc. (CPHI) trades at a FCF yield of 5.92% and a price-to-free-cash-flow ratio of 23.7x. FCF per share stands at $0.03, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

5.92%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$0.03

TTM FCF ÷ Shares Outstanding

Price / FCF

x23.7

Share Price ÷ FCF per Share

EV / FCF (TTM)

x42.1

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

CPHI · cash flow statement · operating / investing / financing

For FY2025, China Pharma Holdings, Inc. generated $0.1M in operating cash flow and spent 0M in capital expenditures, yielding $0.0M in free cash flow.

Operating Activities

+$0.1M

Cash from core business operations

2025-12-31

Investing Activities

−$0.1M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$0.3M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($0.1M) − |CapEx| (0M) = FCF ($0.0M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

CPHI vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

China Pharma Holdings, Inc.YOU

CPHI

$11,010+101.5%0.3%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

China Pharma Holdings, Inc. (CPHI) reported free cash flow of $11,010 for FY2025 (fiscal year ending 2025-12-31), up 101.5% year-over-year. The FCF margin was 0.3%.

Based on available data, China Pharma Holdings, Inc. has maintained positive free cash flow for at least 6 fiscal year(s). FCF peaked at $2.7M in FY2016.

China Pharma Holdings, Inc.'s FCF yield is 5.92% and price-to-FCF ratio is 23.7x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

CPHI free cash flow · 8 questions

China Pharma Holdings, Inc. free cash flow was $11,010 for FY2025, up 101.5% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $134,492.

CPHI free cash flowCPHI FCFCPHI FCF 2025CPHI free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · China Pharma Holdings, Inc. · China Pharma Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026